Ignite Creation Date:
2024-05-06 @ 10:43 AM
Last Modification Date:
2024-10-26 @ 12:34 PM
Study NCT ID:
NCT03335514
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2017-11-03
Brief Title:
GALNT4 in Patients With Acute Coronary Syndrome
Sponsor:
The First Affiliated Hospital of Dalian Medical University
Organization:
The First Affiliated Hospital of Dalian Medical University
Study Overview
Official Title:
Changes of GALNT4 and the Relationship With PSGL-1on Monocytes and Hs-CRP in Blood of Patients With Coronary Heart Disease
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The expression of GALNT4 in blood with acute coronary syndrome
Detailed Description:
Emerging evidences have linked GALNTs to cardiovascular disease or susceptibility to CADGALNT4 a member of the GalNAc-Ts familycontributes to the initiation of O-linked Polymorphisms in GALNT4 have been linked with incidence of MI in an Irish population probably that O-glycosylation of PSGL-1 by GalNAc-T4 may be important for many P-selectin mediated inflammationHowever there is few relevant studies about the expression of GALNT4 in patients with acute coronary syndromeThis study valuates the expression of GALNT4 in patients with acute coronary syndrome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None